RIL
CRDF icon

Rothschild Investment LLC’s Cardiff Oncology CRDF Stock Holding History

Rothschild Investment LLC’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18 Buy
+11
New +$23 ﹤0.01% 3545

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Rothschild Investment LLC's CRDF Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in Cardiff Oncology (CRDF) in Q1 2026: 11 shares worth $18. The stake represents ﹤0.01% of the portfolio and ranks #3545 among its holdings.

116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Rothschild Investment LLC held 11 shares of Cardiff Oncology worth $18 as of Q1 2026.
  • Cardiff Oncology was a new Rothschild Investment LLC position in Q1 2026.
  • Cardiff Oncology made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3545 holding.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.